Searched for
EMCURE PHARMACEUTICALS LTD
Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 croreEmcure Pharmaceuticals Ltd has posted a remarkable consolidated net profit of Rs 325.06 crore for the September quarter, reflecting substan...- Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 croreEmcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore....
- Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun PharmaIndian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC face...
- MFs raise stake for 3 straight quarters in 5 mid-cap stocks; shares gain up to 75% YTDMutual funds steadily increased their holdings in 39 BSE midcap stocks for three consecutive quarters through September 2026. While five st...
- AMFI reshuffle: NSE may get largecap status, SBI Fund Management may become midcap in H1 CY27Nuvama expects NSE to enter the largecap category and SBI Funds Management to become a midcap in AMFI’s H1 CY27 reshuffle. Bosch, Siemens E...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian equities extended their recovery, with Nifty gaining 0.33% as moderation in crude and global yields supported sentiment. Sensex slip...
- F&O Talk: Nifty has slipped below its crucial support, says Sudeep Shah; picks 5 stocks for next weekAfter a turbulent trading day, Indian stock indices bounced back significantly as oil prices and bond yields eased. The Sensex and Nifty en...
- DRL, Emcure get approval to make breakthrough HIV drugIndia's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for l...
- Emcure Pharma net profit up 36% at Rs 292 croreEmcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivi...
- Emcure Pharma Q1 profit jumps 36%, revenue rises 23%; appoints Samit Mehta as COO"We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across ...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Emcure Pharma to acquire remaining 20.42% stake in Zuventus Healthcare for Rs 724.9 crEmcure Pharmaceuticals will acquire the remaining 20.42% stake in Zuventus Healthcare Ltd from minority shareholders for ₹724.9 crore, a mo...
- Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug LenacapavirEmcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention a...
- Emcure Pharmaceuticals IPO share allotment likely on Monday. Here's how you can check the status.
- Emcure Pharmaceuticals IPO booked nearly 68 times so far on Day 3. Check GMP and other detailsEmcure Pharmaceuticals IPO sees strong demand with oversubscription. Anchor investors include top names. Company engaged in global pharmace...
- Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other detailsEmcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on ...
- Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issueEmcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximatel...
- Emcure Pharma announces price band for Rs 1,952-crore IPO at Rs 960-1,008/share. Check GMP, other detailsEmcure Pharmaceuticals has announced its initial public offering (IPO) with a price band of Rs 960 to Rs 1,008 per equity share. The subscr...
- Emcure Pharmaceuticals receives SEBI nod for its IPO launchEmcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of ...
- Emcure Pharmaceuticals acquires Canadian company and its marketing arm MarcanMarcan Pharma has over 60 approved products that are mainly available via McKesson and Kohl & Frisch, among other wholesalers, it claimed.
Load More
